tbuckley/cabot-search huggingface dataset:
CORTONE IN LYMPHOBLASTOMA: A CASE REPORT
Authors: W R SULMAN
Journal: Annals of Internal Medicine (1951)

Case Reports1 April 1951CORTONE IN LYMPHOBLASTOMA: A CASE REPORTWILLIAM R. SULMAN, M.D.WILLIAM R. SULMAN, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-34-4-1062 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe following case of lymphoblastoma, in which Cortone was used only after all accepted methods of treatment had failed, is reported because the drug is new and because the literature contains few such accounts.CASE REPORTThe 48 year old owner and manager of a paper box business was first seen by me in October, 1948. The family history was negative except for the fact that one sister was dying of cancer of the breast. The patient was married and had two children, both living and well. He had never been ill, and had been working very hard for the...Bibliography1. AdlersbergSchaeferDrachman DLSR: Hypercholesteremia during cortisone and ACTH therapy, J. A. M. A. 144: 909-914, 1950. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: WILLIAM R. SULMAN, M.D.*Received for publication December 14, 1950. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHigh-Dose Corticoid Therapy in Hodgkin's Disease and other LymphomasTHOMAS C. HALL, M.D., F.A.C.P., OCK SOON CHOI, M.D., ARDESHIR ABADI, M.D., MELVIN J. KRANT, M.D.Die Lymphogranulomatose der HautThe role of corticosteroids in the treatment of malignant lymphomasCytologie und Klinik der Lymphogranulomatose 1 April 1951Volume 34, Issue 4Page: 1062-1065KeywordsBreast cancerChildrenDrugsHereditary nonpolyposis colorectal cancer ePublished: 1 December 2008 Issue Published: 1 April 1951 PDF downloadLoading ...
Post–Sirolimus-Eluting Stent Restenosis Treated With Repeat Percutaneous Intervention
Authors: Pedro A. Lemos, Carlos A.G. van Mieghem, Chourmouzios A. Arampatzis, Angela Hoye, Andrew T.L. Ong, Eugene McFadden, Georgios Sianos, Willem J. van der Giessen, Pim J. de Feyter, Ron T. van Domburg, Patrick W. Serruys
Journal: Circulation (2004)

We evaluated the clinical and angiographic outcomes of patients presenting with restenosis after sirolimus-eluting stent (SES) implantation treated with repeated percutaneous intervention.A total of 24 consecutive patients have undergone repeated percutaneous intervention to treat post-SES restenosis (27 lesions). The restenosis was located within the stent in 93% of lesions. From the 27 lesions, 1 (4%) was re-treated with a bare stent, 3 (11%) were treated with balloon dilatation, and the remaining 23 lesions (85%) were treated with repeated drug-eluting stent implantation (SES in 12 lesions [44%], paclitaxel-eluting stents in 11 lesions [41%]). The event-free survival rate was 70.8% after a median follow-up of 279 days from the post-SES treatment. The overall recurrent restenosis rate was 42.9%. The risk of recurrent restenosis was increased for patients with hypercholesterolemia, previous angioplasty, failed brachytherapy, post-SES restenosis needing early (<6 months) treatment, and post-SES restenosis treated with balloon dilatation. The recurrent restenosis rate of originally de novo lesions re-treated with drug-eluting stents was 18.2%.Even though de novo lesions treated with SES at baseline and re-treated with drug-eluting stents had reasonably better outcomes than other lesion types and strategies, our study shows that the treatment of post-SES restenosis is currently suboptimal and warrants further investigation.
Long-term concentrations of ambient air pollutants and incident lung cancer in California adults: results from the AHSMOG study.Adventist Health Study on Smog.
Authors: W L Beeson, D E Abbey, S F Knutsen
Journal: Environmental Health Perspectives (1998)

The purpose of this study was to evaluate the relationship of long-term concentrations of ambient air pollutants and risk of incident lung cancer in nonsmoking California adults. A cohort study of 6,338 nonsmoking, non-Hispanic, white Californian adults, ages 27-95, was followed from 1977 to 1992 for newly diagnosed cancers. Monthly ambient air pollution data were interpolated to zip code centroids according to home and work location histories, cumulated, and then averaged over time. The increased relative risk (RR) of incident lung cancer in males associated with an interquartile range (IQR) increase in 100 ppb ozone (O3) was 3.56 [95% confidence interval (CI), 1.35-9.42]. Incident lung cancer in males was also positively associated with IQR increases for mean concentrations of particulate matter <10 microm (PM10; RR = 5.21; CI, 1.94-13.99) and SO2 (RR = 2.66; CI, 1.62-4.39). For females, incident lung cancer was positively associated with IQR increases for SO2 (RR = 2.14; CI, 1.36-3.37) and IQR increases for PM10 exceedance frequencies of 50 microg/m3 (RR = 1.21; CI, 0.55-2.66) and 60 microg/m3 (RR = 1.25; CI, 0.57-2.71). Increased risks of incident lung cancer were associated with elevated long-term ambient concentrations of PM10 and SO2 in both genders and with O3 in males. The gender differences for the O3 and PM10 results appeared to be partially due to gender differences in exposure.
Abstract 18139: Myocardial Fibrosis Quantified by Cardiovascular Magnetic Resonance is Associated with Histology and Graft Function After Pediatric Heart Transplantation
Authors: Brian Feingold, Cláudia M Salgado, Miguel Reyes-Múgica, Stacey Drant, Susan A Miller, Peter Kellman, Erik B Schelbert, Timothy C Wong
Journal: Circulation (2014)

Background: Late survival after pediatric heart transplantation (HTx) remains poor. Many late deaths are due to “graft failure,” typically in the presence of vasculopathy and diffuse myocardial fibrosis (DMF) - a process associated with ventricular remodeling and heart failure (HF). Cardiovascular magnetic resonance (CMR)-derived extracellular volume (ECV) is a validated measure of DMF in the absence of edema or infiltrative disease, and predicts outcomes of HF and mortality in adults. We hypothesize that ECV is a meaningful biomarker of graft dysfunction following pediatric HTx. Objective: To test the association of ECV with histologic myocardial fibrosis after pediatric HTx. We also explored associations of ECV with hemodynamic, echocardiographic, and serum measures of graft function. Methods: We prospectively enrolled consecutive HTx recipients who were ≥13 years old and ≥9 months post HTx for ECV quantification at the time of surveillance endomyocardial biopsy (EMB). Fibrosis was quantified on EMB by automated image analysis after picrosirius staining and digital scanning. CMR measures of blood and myocardial T1 from basal and mid short axis slices, along with contemporaneous hematocrit, quantified ECV. Results: Nineteen pts (12 male) underwent CMR at a mean age of 18.4 ± 2.8 yrs (range 14.9 - 24.4 yrs) and a mean time after HTx of 10.4 ± 6.6 yrs (1.0 - 20.7 yrs). Four pts were excluded from analysis due to acute rejection (ISHLT grade ≥2R) on concurrent EMB (n=2) or poor quality imaging (n=2). Mean ECV was 27.1 ± 3.8 (20.9 - 32.1). Late gadolinium enhancement was observed in 1 pt. ECV showed moderate correlations with histologic myocardial fibrosis (r=0.61; p=0.02) and serum b-type natriuretic peptide (r=0.66; p=0.008). There was a trend to correlation with pulmonary capillary wedge pressure (r=0.51; p=0.06). We found no associations of ECV with systolic or diastolic function, time after HTx, or graft age. Conclusions: We demonstrate a novel association of ECV with histologic myocardial fibrosis and serum and hemodynamic markers of HF after pediatric HTx. Given prior observations of myocardial fibrosis in chronic graft failure, these findings suggest that ECV may be a relevant, noninvasive marker of graft dysfunction and a potential therapeutic target.
Prognostic relevance of increased angiogenesis in osteosarcoma
Authors: M. Kreuter, R. Bieker, S. S. Bielack, T. Auras, H. Buerger, G. Gosheger, H. Jurgens, W. E. Berdel, R. M. Mesters
Journal: Journal of Clinical Oncology (2004)

9022 Background: Osteosarcoma, the most frequent primary malignant bone tumor is a chemotherapy-sensitive tumor with survival rates reaching 50 to 80 %. Several reports have demonstrated that neovascularization assessed by intratumoral microvessel density (MVD) correlates with clinicopathological factors and the patients' prognosis in a variety of tumors. However, the role of angiogenesis in osteosarcoma still remains unclear. Methods: Pretherapeutic tumor biopsies of 60 patients with high grade central osteosarcoma, who were treated according to multimodal neoadjuvant protocols of the Cooperative German-Austrian-Swiss Osteosarcoma Study Group, were evaluated for intratumoral microvessel density. MVD was analyzed with regard to demographic and tumor-related variables, response, and survival. Results: The median intratumoral microvessel count was 52 (interquartile range 31–77). At a median follow up period of 1274 days patients with a high (≥ 53) MVD had significantly better 5- and 10-year overall survival rates with 84 % than patients with low (≤ 52) MVD with 49 % (p = 0.0029, Cox regression analysis). Furthermore a better relapse free survival for high MVD patients (p = 0.0064) was observed. In a subgroup analysis of 47 patients with primary high grade central osteosarcoma of the extremities without primary metastases, patients with high MVD showed significant better 5- and 10-year overall survival rates with 91 % versus 61 % for low MVD (p = 0,039). Cox regression analysis revealed that MVD was an independent prognostic factor for survival. A good response to chemotherapy (histological grading scale of Salzer-Kuntschik) correlated significantly with a high degree of MVD (r = 0.3; p = 0.033). Conclusions: Increased angiogenesis is a prognostic indicator for better survival and response to chemotherapy in patients with osteosarcoma. Thus, determination of MVD might be useful in selecting patients for further neoadjuvant treatment decisions. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Organization for supporting children with cancer, City of Viersen, Germany
The allergen Bet v 1 in fractions of ambient air deviates from birch pollen counts
Authors: J. T. M. Buters, I. Weichenmeier, S. Ochs, G. Pusch, W. Kreyling, A. J. F. Boere, W. Schober, H. Behrendt
Journal: Allergy (2010)

Proof is lacking that pollen count is representative for allergen exposure, also because allergens were found in nonpollen-bearing fractions of ambient air.We monitored simultaneously birch pollen and the major birch pollen allergen Bet v 1 in different size fractions of ambient air from 2004 till 2007 in Munich, Germany.Air was sampled with a ChemVol high-volume cascade impactor equipped with stages for particulate matter (PM)>10 microm, 10 microm>PM>2.5 microm, and 2.5 microm>PM>0.12 microm. Allergen was determined with a Bet v 1-specific ELISA. Pollen count was assessed with a Burkard pollen trap. We also measured the development of allergen in pollen during ripening.About 93 +/- 3% of Bet v 1 was found in the PM > 10 microm fraction, the fraction containing birch pollen. We did not measure any Bet v 1 in 2.5 microm > PM > 0.12 microm. Either in Munich no allergen was in this fraction or the allergen was absorbed to diesel soot particles that also deposit in this fraction. Pollen released 115% more Bet v 1 in 2007 than in 2004. Also within 1 year, the release of allergen from the same amount of pollen varied more than 10-fold between different days. This difference was explained by a rapidly increasing expression of Bet v 1 in pollen in the week just before pollination. Depending on the day the pollen is released during ripening, its potency varies.In general, pollen count and allergen in ambient air follow the same temporal trends. However, because a 10-fold difference can exist in allergen potency of birch pollen, symptoms might be difficult to correlate with pollen counts, but perhaps better with allergen exposure.
Abstract 14722: Dual-Targeted Microbubbles Improve the Detection of Previously Ischemic Myocardium by Echocardiography
Authors: Dan Lin, Yikui Tian, Alexander L Klibanov, John A Hossack, Brent A French
Journal: Circulation (2014)

Introduction: Echocardiography using targeted microbubbles (MB) has been shown to detect previously-ischemic regions of myocardium by molecularly targeting cell adhesion molecules that are displayed on the activated endothelial surface after ischemia/reperfusion injury. We hypothesized that the accuracy and sensitivity of detection could be improved by constant infusion and dual-targeting, respectively. Methods: Ischemia/reperfusion injury was induced in 8 male C57BL/6 mice with 15-min LAD occlusions. After 2h of reperfusion, hearts of the closed-chest mice were imaged in long-axis with a Sequoia 15L8 transducer at 14 MHz. Each mouse received 3 of 4 MB preparations in random order: Sialyl Lewis X MB (MBX), anti-VCAM MB (MBV), Sialyl Lewis X + anti-VCAM MB (MBD), and isotype control MB (MBI). MB concentrations were approximately 200x10^6/mL, and 100 μL were infused at a constant rate of 25 μL/min via tail vein catheter. After imaging, mouse hearts were excised and stained with TTC/Phthalo blue dye to assess area at risk, and compared to regional time intensity curve (RTIC) retrieved from video data (Panel A). Results: Example RTIC for MBD shows enhanced MB signals during and after MB infusion in the anterior apical region of the heart (Panel A). In Panel B, normalized intensities are significantly higher for MBD, MBX, and MBV, compared to MBI (p&lt;0.05). Furthermore, normalized intensity for MBD is higher than both MBX and MBV (p&lt;0.05). Receiver operating curve analysis using blue dye as the gold standard showed accurate detection of both ischemic and non-ischemic regions using MBD (AUC = 0.90), MBX (AUC = 0.89), and MBV (AUC = 0.97). Conclusions: Molecular imaging of endothelial cell adhesion molecules in closed-chest mice is possible using constant infusion of MB. Dual-targeted MB yield greater MB signals than single-targeted MB when delivered using constant infusion, improving both the sensitivity and accuracy of this technique to measure risk regions in intact mice.
Effect of Lenient Versus Strict Rate Control on Cardiac Remodeling in Patients With Atrial Fibrillation
Authors: Marcelle D. Smit, Harry J.G.M. Crijns, Jan G.P. Tijssen, Hans L. Hillege, Marco Alings, Ype S. Tuininga, Hessel F. Groenveld, Maarten P. Van den Berg, Dirk J. Van Veldhuisen, Isabelle C. Van Gelder
Journal: Journal of the American College of Cardiology (2011)
Relationship between vitamin D status and response to hepatitis C virus therapy
Authors: Matthew T. Kitson, Christoph Sarrazin, Pierluigi Toniutto, Stuart K. Roberts
Journal: Hepatology (2015)

Potential conflict of interest: Nothing to report. To the Editor: We read with interest the recently published meta‐analysis by García‐Álvarez et al.1 evaluating vitamin D status and sustained virological response (SVR) to interferon‐based antiviral therapy in chronic hepatitis C virus with or without human immunodeficiency virus coinfection. They found that a 25‐hydroxyvitamin D (25[OH]D) level <20 ng/mL was associated with lower odds of achieving SVR (odds ratio = 0.53, 95% confidence interval 0.34‐0.67) in 1406 patients. We performed a similar meta‐analysis in a larger cohort of 2605 hepatitis C virus–monoinfected patients but contrarily found no association between mean 25(OH)D level and SVR (odds ratio = 1.44, 95% confidence interval 0.92‐2.26; P = 0.11).2 While the two meta‐analyses differ in their inclusion of human immunodeficiency virus–infected patients, we note that similar findings of a relationship between SVR and 25(OH)D level were obtained in their subgroup analysis of hepatitis C virus monoinfection. We therefore suggest that the discordance of findings between the two studies likely arises from some methodologic flaws in their study. First, three of the 11 studies included in the SVR meta‐analysis related to the same Italian cohort of approximately 200 patients,3 meaning that each patient from this cohort has been evaluated three times. In total their SVR meta‐analysis involved 1010 patients when studies evaluating the same cohort of patients multiple times are excluded. Second, five large studies from Europe and Australia, four of which were published in detail by us and involved a combined total of 1569 patients, were not included in the meta‐analysis despite being readily identifiable using the stated search strategy. Third, the meta‐analysis included only studies in which 25(OH)D level was assessed as a categorical rather than continuous variable. This is subject to potential bias as standard definitions for vitamin D insufficiency and deficiency vary worldwide and according to the unit of measurement. Fourth, one included study involved patients receiving vitamin D supplementation despite this being a stated exclusion criterion. Finally, none of the above issues were formally addressed anywhere in the manuscript as caveats to the study's conclusions. These methodologic issues, particularly in reference to the key studies included and excluded, cast doubt on the validity of their findings, which the reader should be aware of when evaluating the study's positive conclusions.
SIRT1 modulates expression of matrix metalloproteinases in human dermal fibroblasts
Authors: K. Ohguchi, T. Itoh, Y. Akao, H. Inoue, Y. Nozawa, M. Ito
Journal: British Journal of Dermatology (2010)

Journal Article SIRT1 modulates expression of matrix metalloproteinases in human dermal fibroblasts Get access K. Ohguchi, K. Ohguchi Gifu International Institute of Biotechnology, 1‐1 Naka‐Fudogaoka, Kakamigahara, Gifu 504‐0838, Japan Correspondence: Kenji Ohguchi. E‐mail: kohguchi@giib.or.jp Search for other works by this author on: Oxford Academic Google Scholar T. Itoh, T. Itoh Gifu International Institute of Biotechnology, 1‐1 Naka‐Fudogaoka, Kakamigahara, Gifu 504‐0838, Japan Search for other works by this author on: Oxford Academic Google Scholar Y. Akao, Y. Akao Gifu International Institute of Biotechnology, 1‐1 Naka‐Fudogaoka, Kakamigahara, Gifu 504‐0838, Japan Search for other works by this author on: Oxford Academic Google Scholar H. Inoue, H. Inoue Department of Food Science and Nutrition, Faculty of Human Life and Environment, Nara Women's University, Kita‐Uoya‐Nishimachi, Nara 630‐8506, Japan Search for other works by this author on: Oxford Academic Google Scholar Y. Nozawa, Y. Nozawa Gifu International Institute of Biotechnology, 1‐1 Naka‐Fudogaoka, Kakamigahara, Gifu 504‐0838, Japan Search for other works by this author on: Oxford Academic Google Scholar M. Ito M. Ito Gifu International Institute of Biotechnology, 1‐1 Naka‐Fudogaoka, Kakamigahara, Gifu 504‐0838, Japan Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 163, Issue 4, 1 October 2010, Pages 689–694, https://doi.org/10.1111/j.1365-2133.2010.09825.x Published: 01 October 2010
Persistent, Nontender Lip Swelling in a Patient With HIV
Authors: Ryan Gillihan, Ryan Fischer, Jennifer Cafardi
Journal: JAMA Dermatology (2015)

A man in his early 40s with a history of verruca vulgaris, dyshidrotic eczema, and HIV presented with a chief complaint of dry, swollen lips, a 1-month history of "puffy and bumpy" lips, and a sometimes "dry and scaly" lower lip but no bleeding. What is your diagnosis?
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Authors: Judith S. Sebolt-Leopold, David T. Dudley, Roman Herrera, Keri Van Becelaere, Amy Wiland, Richard C. Gowan, Haile Tecle, Stephen D. Barrett, Alexander Bridges, Sally Przybranowski, W.R. Leopold, Alan R. Saltiel
Journal: Nature Medicine (1999)
Methodological Standards in Human vs Animal Clinical Trials
Authors: Kennon Heard, Vikhyat S Bebarta, Steven R Lowenstein
Journal: JAMA (2005)

To the Editor: Dr Pluta and colleagues found a significant benefit from the use of sodium nitrite in preventing delayed vasospasm following subarachnoid hemorrhage in a study of 14 monkeys.1 We are concerned about these conclusions given certain aspects of the study design.
Overexpression of imprinted DLK1 in epithelial ovarian cancer
Authors: Susan K. Murphy, Alison H. Gusberg, Zhiqing Huang, Lauren R. Simel, Regina S. Whitaker, Andrew Berchuck
Journal: Cancer Research (2006)

1571  Purpose. Paternally expressed DLK1 (Delta, Drosophila, Homolog-Like 1) is located within the imprinted cluster of genes on human chromosome 14q32.2 that includes the maternally expressed gene MEG3. DLK1 encodes a protein that regulates early growth and differentiation while the MEG3 locus encodes an untranslated RNA. The purpose of this study was to determine whether overexpression of the imprinted gene DLK1 is associated with loss of imprinting and/or deregulation of MEG3 transcription in serous epithelial ovarian cancer. Procedures. Gene expression was measured using Affymetrix U133A Genechips and the robust multiarray average algorithm. Methylation status of the differentially methylated region (DMR) proximal to the MEG3 promoter was analyzed using bisulfite sequencing followed by phosphorimaging. Allelic expression of DLK1 was established by nucleotide sequencing of an exonic single nucleotide polymorphism in cDNA from heterozygous specimens. Results. Previous microarray analysis of 76 serous epithelial ovarian cancers and 12 serous borderline tumors indicated that DLK1 expression was substantially elevated (>3-fold higher than normal ovarian surface epithelium) in 100% (12 of 12) of the borderline tumors, in 67% (8 of 12) of stage I/II cancers, and in 23% (15 of 64) of stage III/IV cancers. Using linear regression, MEG3 expression was found to positively correlate with the expression of DLK1 in borderline and malignant serous tumors (p
Tofacitinib Citrate for the Treatment of Vitiligo
Authors: Brittany G. Craiglow, Brett A. King
Journal: JAMA Dermatology (2015)

<h3>Importance</h3> Vitiligo is a common condition that is often emotionally devastating for patients. At present, no reliably effective treatments are available. <h3>Observations</h3> Recent advances in the understanding of the pathogenesis of vitiligo suggest that Janus kinase inhibitors may be a therapeutic option. We report a case of generalized vitiligo for which treatment with tofacitinib citrate, an oral Janus kinase 1/3 inhibitor, resulted in significant repigmentation. <h3>Conclusions and Relevance</h3> The results suggest that tofacitinib and other Janus kinase inhibitors may be effective in the treatment of vitiligo. Additional studies will be needed to confirm their efficacy and to explore their safety.
Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use
Authors: Jelle O. Barentsz, Jeffrey C. Weinreb, Sadhna Verma, Harriet C. Thoeny, Clare M. Tempany, Faina Shtern, Anwar R. Padhani, Daniel Margolis, Katarzyna J. Macura, Masoom A. Haider, Francois Cornud, Peter L. Choyke
Journal: European Urology (2015)
The Misleading Vividness of a Physician Requesting Futile Treatment
Authors: Colleen M. Gallagher, Jeffrey S. Farroni, Jessica A. Moore, Joseph L. Nates, Maria A. Rodriguez
Journal: The American Journal of Bioethics (2015)

"The Misleading Vividness of a Physician Requesting Futile Treatment." The American Journal of Bioethics, 15(8), pp. 52–53